组胺
免疫球蛋白E
卵清蛋白
免疫学
医学
过敏性炎症
肥大细胞
炎症
过敏反应
细胞因子
脱颗粒
白细胞介素5
白细胞介素33
促炎细胞因子
化学
白细胞介素
嗜酸性粒细胞
类胰蛋白酶
过敏
敏化
药理学
抗原
抗体
作者
Thi Bui,Chun Hua Piao,Chang Ho Song,Ok Hee Chai
标识
DOI:10.1016/j.intimp.2017.08.029
摘要
Allergic rhinitis is a common heterogeneous chronic upper airway disorder and is an IgE-mediated inflammation characterized by one or more nasal symptoms such as sneezing, itching, nasal discharge, rhinorrhea, post nasal drainage and nasal blockage. In the present study, the effects of skullcapflavone II (SCFII) on upper airway inflammation, Th2 cytokines, and NF-κB signaling in an ovalbumin (OVA)-induced allergic rhinitis (AR) murine model in vivo were investigated. OVA-induced AR mice increased nasal symptoms, eosinophils and mast cells infiltration into nasal cavity, OVA-specific IgE/IgG1 and histamine in serum, Th2 cytokines including IL-13 and GATA3, and NF-κB signaling in NALF and lung homogenate. Interestingly, treatment of SCFII reduced the levels of OVA-specific IgE/IgG1 and histamine in serum, of Th2 cytokines and of NF-κB signaling in the NALF and the lung homogenate, and histopathological changes in the nasal tissue and the lung. Also, dexamethasone suppressed such increases. The results of this study suggested that SCFII may ameliorate allergic inflammation of upper airway in AR mice model by blocking the Th2 cytokine production, the NF-κB signal pathway and the mast cell histamine release. Taken together, we suggest that SCFII may be used as a therapeutic agent for patients with Th2-mediated or mast cell-mediated allergic diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI